Henry Schein (HSIC) 10-Q 5 Nov 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 28, 2024	Oct. 28, 2024
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-28
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 28, 2024
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		124,681,294

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Sep. 28, 2024	Dec. 30, 2023
Current assets:
Cash and cash equivalents		$ 126	$ 171
Accounts receivable, net of allowance for credit losses of $86 and $83	[1]	1,660	1,863
Inventories, net		1,754	1,815
Prepaid expenses and other		607	639
Total current assets		4,147	4,488
Property and equipment, net		540	498
Operating lease right-of-use assets		304	325
Goodwill		3,986	3,875
Other intangibles, net		1,100	916
Investments and other		528	471
Total assets		10,605	10,573
Current liabilities:
Accounts payable		1,026	1,020
Bank credit lines		638	264
Current maturities of long-term debt		109	150
Operating lease liabilities		77	80
Accrued expenses:
Payroll and related		289	332
Taxes		159	137
Other		631	700
Total current liabilities		2,929	2,683
Long-term debt	[1]	1,906	1,937
Deferred income taxes		123	54
Operating lease liabilities		262	310
Other liabilities		414	436
Total liabilities		5,634	5,420
Redeemable noncontrolling interests		832	864
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value, 1,000,000 shares authorized, none outstanding		0	0
Common stock, $0.01 par value, 480,000,000 shares authorized,125,154,194 outstanding on September 28, 2024 and 129,247,765 outstanding on December 30, 2023		1	1
Additional paid-in capital		0	0
Retained earnings		3,766	3,860
Accumulated other comprehensive loss		(264)	(206)
Total Henry Schein, Inc. stockholders' equity		3,503	3,655
Noncontrolling interests		636	634
Total stockholders' equity		4,139	4,289
Total liabilities, redeemable noncontrolling interests and stockholders' equity		$ 10,605	$ 10,573
[1] Amounts presented include balances held by our consolidated variable interest entity (“VIE”). December 30, 2023, includes trade accounts receivable of $ 341 284 210 million and $ 210

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Current assets:
Accounts receivable, allowances for credit losses (in dollars)	$ 86	$ 83
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	125,154,194	129,247,765
Variable Interest Entity, Primary Beneficiary [Member] | Recourse [Member]
Stockholders' equity:
Liabilities of VIE	$ 210	$ 210
Asset Pledged as Collateral [Member] | Variable Interest Entity, Primary Beneficiary [Member]
Stockholders' equity:
Pledged assets	$ 341	$ 284

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract]
Net sales	$ 3,174	$ 3,162	$ 9,482	$ 9,322
Cost of sales	2,181	2,167	6,459	6,386
Gross profit	993	995	3,023	2,936
Operating expenses:
Selling, general and administrative	724	725	2,296	2,149
Depreciation and amortization	64	59	188	152
Restructuring costs	48	11	73	59
Operating income	157	200	466	576
Other income (expense):
Interest income	7	6	18	12
Interest expense	(34)	(25)	(96)	(58)
Other, net	(2)	(2)	(1)	(2)
Income before taxes, equity in earnings of affiliates and noncontrolling interests	128	179	387	528
Income taxes	(32)	(39)	(97)	(119)
Equity in earnings of affiliates, net of tax	3	3	12	10
Net income	99	143	302	419
Less: Net income attributable to noncontrolling interests	0	(6)	(6)	(21)
Net income attributable to Henry Schein, Inc.	$ 99	$ 137	$ 296	$ 398
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 0.79	$ 1.06	$ 2.32	$ 3.04
Diluted (in dollars per share)	$ 0.78	$ 1.05	$ 2.30	$ 3.02
Weighted-average common shares outstanding:
Basic (in shares)	126,124,715	130,388,353	127,550,045	130,888,717
Diluted (in shares)	127,054,934	131,442,135	128,498,494	132,149,172

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]
Net income	$ 99	$ 143	$ 302	$ 419
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	58	(45)	(58)	(17)
Unrealized gain (loss) from hedging activities	(18)	6	(3)	2
Other comprehensive income (loss), net of tax	40	(39)	(61)	(15)
Comprehensive income	139	104	241	404
Comprehensive income attributable to noncontrolling interests:
Net income	0	(6)	(6)	(21)
Foreign currency translation loss (gain)	(12)	2	3	1
Comprehensive income attributable to noncontrolling interests	(12)	(4)	(3)	(20)
Comprehensive income attributable to Henry Schein, Inc.	$ 127	$ 100	$ 238	$ 384

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock $.01 Par Value [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 31, 2022	$ 4,095	$ 1	$ 0	$ 3,678	$ (233)	$ 649
Beginning Balance, shares (in shares) at Dec. 31, 2022		131,792,817
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	408			398		10
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	(16)				(16)
Unrealized gain (loss) from hedging activities, net of tax	2				2
Distributions to noncontrolling shareholders	(28)					(28)
Change in fair value of redeemable securities	14		14
Noncontrolling interests and adjustments related to business acquisitions	(2)		0			(2)
Repurchases and retirement of common stock - Value	(201)		(26)	(175)
Repurchases and retirement of common stock - Shares		(2,521,695)
Stock-based compensation expense - Value	38		38
Stock-based compensation expense - Shares		1,060,883
Stock issued upon exercise of stock options - Value	1		1
Stock issued upon exercise of stock options - Shares		19,744
Shares withheld for payroll taxes - Value	(32)		(32)
Shares withheld for payroll taxes - Shares		(415,048)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		(818)
Transfer of charges in excess of capital	0		4	(4)
Ending Balance at Sep. 30, 2023	4,280	$ 1	0	3,897	(247)	629
Ending Balance, shares (in shares) at Sep. 30, 2023		129,935,883
Beginning Balance at Jul. 01, 2023	4,186	$ 1	0	3,769	(210)	626
Beginning Balance, shares (in shares) at Jul. 01, 2023		130,576,806
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	141			137		4
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	(43)				(43)
Unrealized gain (loss) from hedging activities, net of tax	6				6
Distributions to noncontrolling shareholders	(1)					(1)
Change in fair value of redeemable securities	28		28
Noncontrolling interests and adjustments related to business acquisitions	(1)		(1)			0
Repurchases and retirement of common stock - Value	(50)		(6)	(44)
Repurchases and retirement of common stock - Shares		(659,681)
Stock-based compensation expense - Value	14		14
Stock-based compensation expense - Shares		23,985
Stock issued upon exercise of stock options - Shares		3,884
Shares withheld for payroll taxes - Value	0		0
Shares withheld for payroll taxes - Shares		(9,183)
Settlement of stock-based compensation awards - Value	0		0
Settlement of stock-based compensation awards - Shares		72
Transfer of charges in excess of capital	0		(35)	35
Ending Balance at Sep. 30, 2023	4,280	$ 1	0	3,897	(247)	629
Ending Balance, shares (in shares) at Sep. 30, 2023		129,935,883
Beginning Balance at Dec. 30, 2023	$ 4,289	$ 1	0	3,860	(206)	634
Beginning Balance, shares (in shares) at Dec. 30, 2023	129,247,765	129,247,765
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	$ 302			296		6
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	(54)				(55)	1
Unrealized gain (loss) from hedging activities, net of tax	(3)				(3)
Distributions to noncontrolling shareholders	(5)					(5)
Purchase of noncontrolling interests	(8)		(7)			(1)
Change in fair value of redeemable securities	(87)		(87)
Noncontrolling interests and adjustments related to business acquisitions	(7)		(8)			1
Repurchases and retirement of common stock - Value	(313)		(42)	(271)
Repurchases and retirement of common stock - Shares		(4,368,510)
Stock-based compensation expense - Value	30		30
Stock-based compensation expense - Shares		337,753
Stock issued upon exercise of stock options - Value	$ 3		3
Stock issued upon exercise of stock options - Shares	48,842	47,688
Shares withheld for payroll taxes - Value	$ (9)		(9)
Shares withheld for payroll taxes - Shares		(110,566)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		64
Transfer of charges in excess of capital			119	(119)
Ending Balance at Sep. 28, 2024	$ 4,139	$ 1	0	3,766	(264)	636
Ending Balance, shares (in shares) at Sep. 28, 2024	125,154,194	125,154,194
Beginning Balance at Jun. 29, 2024	$ 4,148	$ 1	0	3,803	(292)	636
Beginning Balance, shares (in shares) at Jun. 29, 2024		127,080,545
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	98			99		(1)
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	47				46	1
Unrealized gain (loss) from hedging activities, net of tax	(18)				(18)
Purchase of noncontrolling interests	(2)		(1)			(1)
Change in fair value of redeemable securities	(6)		(6)
Noncontrolling interests and adjustments related to business acquisitions	(3)		(4)			1
Repurchases and retirement of common stock - Value	(137)		(18)	(119)
Repurchases and retirement of common stock - Shares		(1,954,076)
Stock-based compensation expense - Value	10		10
Stock-based compensation expense - Shares		7,655
Stock issued upon exercise of stock options - Value	1		1
Stock issued upon exercise of stock options - Shares		22,448
Shares withheld for payroll taxes - Value	0		0
Shares withheld for payroll taxes - Shares		(2,403)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		25
Transfer of charges in excess of capital	0		17	(17)
Ending Balance at Sep. 28, 2024	$ 4,139	$ 1	$ 0	$ 3,766	$ (264)	$ 636
Ending Balance, shares (in shares) at Sep. 28, 2024	125,154,194	125,154,194

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Net income (loss) attributable to redeemable noncontrolling interests	$ (1)	$ 2	$ 0	$ 11	$ 6
Foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	11	(2)	(4)	(1)	$ 5
Unrealized gain (loss) from foreign currency hedging activities, tax (benefit)	$ (7)	$ 3	$ (1)	$ 1

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income	$ 302	$ 419
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	221	180
Non-cash restructuring charges	11	13
Stock-based compensation expense	30	38
Provision for losses on trade and other accounts receivable	12	7
Benefit from deferred income taxes	(41)	(4)
Equity in earnings of affiliates	(12)	(10)
Distributions from equity affiliates	10	12
Changes in unrecognized tax benefits	3	5
Other	(25)	(11)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	188	(72)
Inventories	38	180
Other current assets	38	(55)
Accounts payable and accrued expenses	(131)	(170)
Net cash provided by operating activities	644	532
Cash flows from investing activities:
Purchases of property and equipment	(112)	(108)
Payments related to equity investments and business acquisitions, net of cash acquired	(223)	(668)
Proceeds from loan to affiliate	3	4
Capitalized software costs	(30)	(30)
Other	(10)	(6)
Net cash used in investing activities	(372)	(808)
Cash flows from financing activities:
Net change in bank credit lines	374	(98)
Proceeds from issuance of long-term debt	120	1,158
Principal payments for long-term debt	(193)	(457)
Debt issuance costs	0	(3)
Proceeds from issuance of stock upon exercise of stock options	3	1
Payments for repurchases and retirement of common stock	(310)	(200)
Payments for taxes related to shares withheld for employee taxes	(9)	(34)
Distributions to noncontrolling shareholders	(36)	(41)
Acquisitions of noncontrolling interests in subsidiaries	(255)	(19)
Net cash provided by (used in) financing activities	(306)	307
Effect of exchange rate changes on cash and cash equivalents	(11)	18
Net change in cash and cash equivalents	(45)	49
Cash and cash equivalents, beginning of period	171	117
Cash and cash equivalents, end of period	$ 126	$ 166

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 28, 2024
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our condensed consolidated financial statements include the accounts of Henry controlled subsidiaries (“we”, “us” and “our”). consolidation. financial decisions are accounted for under the equity method. to conform to the current period presentation. have a material impact on our condensed consolidated financial condition, Our accompanying unaudited condensed consolidated financial statements accounting principles generally accepted in the United States with the instructions to Form 10-Q and Article 10 of Regulation S-X. information and footnote disclosures required by U.S. GAAP for complete The unaudited interim condensed consolidated financial statements should be consolidated financial statements and notes to the consolidated financial on Form 10-K for the year ended December 30, 2023 and with the information available filings with the Securities and Exchange Commission. reflect all adjustments considered necessary for a fair presentation of financial position for the interim periods presented. The preparation of financial statements in conformity with accounting principles States requires us to make estimates and assumptions that affect the reported amounts of disclosure of contingent assets and liabilities at the date of the financial revenues and expenses during the reporting period. operations for the three and nine months ended September 28, 2024 be expected for any other interim period or for the year ending December 28, 2024. Our condensed consolidated financial statements reflect estimates and other things, our goodwill, long-lived asset and definite-lived intangible investment valuation; assessment of the annual effective tax rate; valuation of tax contingencies; the allowance for credit losses; hedging activity; supplier cost for certain share-based performance awards and cash bonus plans; and We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the benefits. debt. and December 30, 2023, certain trade accounts receivable that can were $ 341 284 to us were $ 210 210

Significant Accounting Policies

Significant Accounting Policies and Recently Issued Accounting Standards	9 Months Ended
	Sep. 28, 2024
Significant Accounting Policies and Recently Issued Accounting Standards [Abstract]
Significant Accounting Policies and Recently Issued Accounting Standards	Note 2 – Significant Accounting Policies and Recently Issued Accounting Significant Accounting Policies There have been no material changes in our significant accounting policies during September 28, 2024, as compared to the significant accounting policies on Form 10-K for the year ended December 30, 2023. Recently Issued Accounting Standards In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-01, “ Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, ” which clarifies how to determine whether profits interest and for as a share-based payment arrangement under Topic 718 or within the scope of other guidance. provides an illustrative example with multiple fact patterns and amends Topic 718 to improve its clarity and operability. profits interest awards as compensation to employees or nonemployees can apply the amendments either retrospectively to all periods presented to profits interest awards granted or modified on or after the date an entity must disclose the nature of and reason for the change in accounting principle adoption of the ASU. periods within those fiscal years. impact on our consolidated financial statements. In December 2023, FASB issued ASU 2023-09, “ Income Taxes (Topic Disclosures ,” which requires public business entities to disclose additional respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and It also requires greater detail about individual reconciling items in those items exceeds a specified threshold. ASU requires information pertaining to taxes paid (net of refunds received) and foreign taxes and further disaggregated for specific jurisdictions quantitative threshold. determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event triggered the establishment of the reconciling item and the activity with which The ASU eliminates the historic requirement that entities disclose information benefits having a reasonable possibility of significantly increasing reporting date. permitted for annual financial statements that have not yet been should be applied on a prospective basis; however, retrospective application is permitted. evaluating the impact that ASU 2023-09 will have on our consolidated In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segments ,” which aims to improve financial reporting by requiring disclosure on an annual and interim basis for all public entities to enable investors to analyses. segments. operating decision maker uses to assess segment performance and Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization and depletion expense, to be disclosed under certain circumstances. remove those disclosure requirements and do not change how a public aggregates those operating segments or applies the quantitative thresholds This ASU is effective for fiscal years beginning after December 15, 2023, and interim beginning after December 15, 2024. 2023- 07 will have on our consolidated financial statements.

Cyber Incident

Cyber Incident	9 Months Ended
	Sep. 28, 2024
Cyber Incident [Abstract]
Cyber Incident	Note 3 – Cyber Incident In October 2023 Henry Schein experienced a cyber incident that primarily American and European dental and medical distribution businesses. software, revenue cycle management and patient relationship management our manufacturing businesses were mostly unaffected. ecommerce platform and related applications, which was remediated. During the three and nine months ended September 28, 2024, we had a distribution businesses, which we believe was primarily a result of lower sales year’s cyber incident. During the three and nine months ended September 28, 2024, we 1 9 of expenses directly related to the cyber incident, mostly consisting insurance, subject to certain retentions and policy limitations. have a $ 60 5 September 28, 2024, we received insurance proceeds of $ 10 20 partial insurance recovery of losses related to the cyber incident. the cyber incident are included in the selling, general and administrative statements of income.

Net Sales from Contracts with C

Net Sales from Contracts with Customers	9 Months Ended
	Sep. 28, 2024
Net Sales from Contracts with Customers [Abstract]
Net Sales from Contracts with Customers	Note 4 – Net Sales from Contracts with Customers Net sales are recognized in accordance with policies disclosed in Item the year ended December 30, 2023. Disaggregation of Net Sales The following table disaggregates our net sales by reportable and operating segment Three Months Ended Nine Months Ended September 28, 2024 September 28, 2024 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,089 $ 763 $ 1,852 $ 3,321 $ 2,369 $ 5,690 Medical 1,076 25 1,101 3,060 80 3,140 Total health care distribution 2,165 788 2,953 6,381 2,449 8,830 Technology 190 31 221 565 87 652 Total net sales $ 2,355 $ 819 $ 3,174 $ 6,946 $ 2,536 $ 9,482 Three Months Ended Nine Months Ended September 30, 2023 September 30, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,134 $ 748 $ 1,882 $ 3,447 $ 2,290 $ 5,737 Medical 1,044 26 1,070 2,920 71 2,991 Total health care distribution 2,178 774 2,952 6,367 2,361 8,728 Technology 185 25 210 519 75 594 Total net sales $ 2,363 $ 799 $ 3,162 $ 6,886 $ 2,436 $ 9,322 Contract Liabilities At September 28, 2024, liabilities were $ 76 8 89 9 86 8 respectively. 72 amount that was previously deferred at December 30, 2023. we recognized in net sales $ 70 contract liabilities are included in accrued expenses: other and the non-current other liabilities within our consolidated balance sheets.

Segment Data

Segment Data	9 Months Ended
	Sep. 28, 2024
Segment Data [Abstract]
Segment Data	Note 5 Segment Data We conduct our business through two value-added services. dental businesses serve office-based dental practitioners, dental laboratories, schools, government institutions. medical technicians, dialysis centers, home health, federal and state governments group practices, and integrated delivery networks, among other providers dental and medical groups serve practitioners in 33 The health care distribution reportable segment aggregates our global dental segment distributes consumable products, dental specialty products (including products), pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal equipment (“PPE”) products, vitamins and orthopedic implants. Our global technology and value-added services reportable segment provides added services to health care practitioners. systems for dental practitioners. revenue cycle management and financial services on a non-recourse basis, for practitioners, The following tables present information about our reportable and operating Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Net sales: Health care distribution (1) Dental $ 1,852 $ 1,882 $ 5,690 $ 5,737 Medical 1,101 1,070 3,140 2,991 Total health care distribution 2,953 2,952 8,830 8,728 Technology (2) 221 210 652 594 Total $ 3,174 $ 3,162 $ 9,482 $ 9,322 Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Operating Income: Health care distribution $ 118 $ 160 $ 390 $ 471 Technology 39 40 76 105 Total $ 157 $ 200 $ 466 $ 576

Business Acquisitions

Business Acquisitions	9 Months Ended
	Sep. 28, 2024
Business Acquisitions [Abstract]
Business Acquisitions	Note 6 Business Acquisitions Our acquisition strategy is focused on investments in companies that our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies. Acquisition of TriMed On April 1, 2024, we acquired a 60 % voting equity interest in TriMed Inc. (“TriMed”), a global developer of solutions for the orthopedic treatment of lower and upper extremities, headquartered The following table aggregates paid and net assets acquired in the TriMed acquisition: 2024 Acquisition consideration: Cash $ 141 Deferred consideration 22 Redeemable noncontrolling interests 153 Total consideration $ 316 Identifiable assets acquired and liabilities assumed: Current assets $ 36 Intangible assets 221 Other noncurrent assets 10 Current liabilities (9) Deferred income taxes (62) Other noncurrent liabilities (6) Total identifiable 190 Goodwill 126 Total net assets acquired $ 316 Goodwill is a result of synergies that are expected to originate from the acquisition as well as potential of TriMed. The following table summarizes the identifiable intangible assets acquired 2024 Weighted Average Lives (in years) Product development $ 204 9 Trademarks / Tradenames 9 7 In process research & development 8 Not Applicable Total $ 221 Except for in-process research and development (“IPR&D”), intangible assets acquisition are being amortized over their estimated useful lives The IPR&D is accounted for as an indefinite-lived intangible asset and abandonment of the associated research and development efforts. periodically if an indicator of impairment exists during the period until completion. The accounting for the acquisition of TriMed has not been completed in several areas, pending assessments of accounts receivable, right-of-use lease assets, and non-income based taxes. measurement period adjustments. year from the acquisition date. Pro forma financial information has not been presented because the three and nine months ended September 28, 2024 was immaterial statements. Other 2024 Acquisitions During the nine months ended September 28, 2024, we acquired companies technology and value-added services segments. 51 % to 100 %. 113 of $ 59 64 customer relationships and lists of $ 33 24 $ 5 2 assets were 11 7 9 5 During the nine months ended September 28, 2024, we completed the accounting occurred in fiscal year 2024 and we did not record any material measurement acquisitions. including but not limited to pending assessment of accounts receivable, accrued liabilities and non-income based taxes. Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions for us, as well as the expected growth potential. purposes. During the three and nine months ended September 28, 2024, in connection interest of an affiliate, we recognized a gain of approximately $ 19 of our previously held equity investment, using a discounted cash flow The impact of these acquisitions, individually and in the aggregate, was consolidated financial statements. 2023 Acquisitions Acquisition of Shield Healthcare On October 2, 2023, we acquired a 90 % voting equity interest in Shield Healthcare, Inc. (“Shield”), a homecare medical products delivered directly to patients in their homes, 348 (including cash paid of $ 289 22 of $ 37 items such as incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies. Additionally, Shield offers continuous glucose monitoring devices directly to patients in their homes. During the quarter ended June 29, 2024, we completed the accounting for our table aggregates the final fair value, as of the date of the acquisition, of consideration in the Shield acquisition: Final Allocation Acquisition consideration: Cash $ 289 Deferred consideration 22 Redeemable noncontrolling interests 37 Total consideration $ 348 Identifiable assets acquired and liabilities assumed: Current assets $ 41 Intangible assets 166 Other noncurrent assets 16 Current liabilities (24) Deferred income taxes (43) Other noncurrent liabilities (7) Total identifiable 149 Goodwill 199 Total net assets acquired $ 348 Goodwill is a result of synergies that are expected to originate from the acquisition as well as potential of Shield. The following table summarizes the identifiable intangible assets acquired 2023 Weighted Average (in years) Customer relationships and lists $ 156 12 Trademarks / Tradenames 10 5 Total $ 166 Pro forma financial information has not been presented because the impact of to our consolidated financial statements. Acquisition of S.I.N. Implant System On July 5, 2023, we acquired a 100 % voting equity interest in S.I.N. Implant System (“S.I.N.”) for consideration $ 329 procedures and is focused on advancing the development of value-priced dental the distribution of its products into the United States and other During the quarter ended June 29, 2024, we completed the accounting for our table aggregates the final fair value, as of the date of acquisition, of consideration the S.I.N. acquisition: Final Allocation Acquisition consideration: Cash $ 329 Total consideration $ 329 Identifiable assets acquired and liabilities assumed: Current assets $ 73 Intangible assets 87 Other noncurrent assets 48 Current liabilities (33) Long-term debt (22) Deferred income taxes (38) Other noncurrent liabilities (27) Total identifiable 88 Goodwill 241 Total net assets acquired $ 329 Goodwill is a result of synergies that are expected to originate from the acquisition as well as potential of S.I.N. The following table summarizes the identifiable intangible assets acquired 2023 Weighted Average (in years) Customer relationships and lists $ 38 7 Product development 36 8 Trademarks / Tradenames 13 10 Total $ 87 Pro forma financial information has not been presented because the impact to our consolidated financial statements. Acquisition of Biotech Dental On April 5, 2023, we acquired a 57 % voting equity interest in Biotech Dental, a provider of dental implants, aligners, individualized prosthetics and innovative digital dental software based consideration of $ 423 216 25 controlled subsidiary, and redeemable noncontrolling interests of $ 182 important solutions for dental practices and dental labs, including Nemotec, planning and diagnostic software using open architecture that connects disparate view of the patient, offering greater diagnostic accuracy and an improved patient During the quarter ended March 30, 2024, we completed the accounting following table aggregates the final fair value, as of the date of acquisition, acquired in the Biotech Dental acquisition: Final Allocation Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 74 Intangible assets 189 Other noncurrent assets 69 Current liabilities (60) Long-term debt (73) Deferred income taxes (53) Other noncurrent liabilities (20) Total identifiable 126 Goodwill 297 Total net assets acquired $ 423 Goodwill is a result of synergies that are expected to originate from the acquisition as well as potential of Biotech Dental. The following table summarizes the identifiable intangible assets acquired Dental: 2023 Weighted Average Lives (in years) Product development $ 124 10 Customer relationships and lists 47 9 Trademarks / Tradenames 18 7 Total $ 189 Pro forma financial information has not been presented because the immaterial to our condensed consolidated financial statements. Other 2023 Acquisitions During the year ended December 30, 2023, in addition to those noted above, health care distribution and technology and value-added services segments. between 51 % to 100 %. $ 0 38 statements of income, representing a change in the fair value of contingent acquisition. During the nine months ended September 28, 2024, we completed the accounting acquisitions. consolidated financial statements relating to changes in estimated values of contingent consideration assets and liabilities. Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions for us, as well as the expected growth potential. purposes. Pro forma financial information for our 2023 acquisitions has not been acquisitions was immaterial to our condensed consolidated Acquisition Costs During the three and nine months ended September 28, 2024, we 2 5 costs, respectively. 6 18 million in acquisition costs, respectively. condensed consolidated statements of income.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 28, 2024
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 7 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or transaction between market participants at the measurement date. (1) market participant assumptions developed based on market data obtained inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the in active markets for identical assets or liabilities (Level 1) and the lowest priority The three levels of the fair value hierarchy are described as follows: • measurement date. • either directly or indirectly. quoted prices for identical or similar assets or liabilities in markets prices that are observable for the asset or liability; and inputs that are observable market data by correlation or other means. • The following section describes the fair values of our financial instruments measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated Certain of our notes receivable contain variable interest rates. estimate of fair value based on the interest rates in the applicable fair value is based on Level 3 inputs within the fair value hierarchy. Debt The fair value of our debt (including bank credit lines, current maturities based on Level 3 inputs within the fair value hierarchy, and as of September 28, 2024 and December 30, 2023 was estimated at $ 2,653 2,351 value of our debt include market conditions, such as interest rates and credit Derivative contracts Derivative contracts are valued using quoted market prices and instruments primarily include foreign currency forward agreements, forecasted foreign currency forward contracts, interest rate swaps and total return swaps. The fair values for the majority of our foreign currency derivative contracts rate to a published forward price of the underlying market rates, which transactions that are classified within Level 2 of the fair value hierarchy. The fair value of the interest rate swap, which is classified within Level 2 by comparing our contract rate to a forward market rate as of the The fair value of total return swaps is determined by valuing the underlying using market-on-close pricing by industry providers as of the valuation fair value hierarchy. Redeemable noncontrolling interests The values for redeemable noncontrolling interests are based on recent earnings that are classified within Level 3 of the fair value hierarchy. Intangible Assets Assets measured on a non-recurring basis at fair value include intangibles. classified as Level 3 within the fair value hierarchy. Contingent Consideration We estimate the fair value of contingent consideration payments as part of the acquisition price and record the estimated fair value of contingent consideration as a liability on our transactions accounted for as business combinations, subsequent changes consideration payments are included in selling, general, and administrative statements of income. control, subsequent changes in the estimated fair value of contingent consideration additional paid-in capital in our condensed consolidated balance sheet. fair value on a recurring basis using significant unobservable inputs classified hierarchy. scenarios, to determine the fair value of the contingent consideration liabilities on reporting period. free rates, and credit spread. The following table presents our assets and liabilities that are measured and basis classified under the appropriate level of the fair value hierarchy as of 2023: September 28, 2024 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ - $ - $ - Derivative contracts undesignated - 2 - 2 Total return - 2 - 2 Total assets $ - $ 4 $ - $ 4 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 3 - 3 Contingent consideration - - 49 49 Total liabilities $ - $ 21 $ 49 $ 70 Redeemable noncontrolling interests $ - $ - $ 832 $ 832 December 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total return - 4 - 4 Total assets $ - $ 6 $ - $ 6 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 20 $ - $ 20 Redeemable noncontrolling interests $ - $ - $ 864 $ 864

Debt

Debt	9 Months Ended
	Sep. 28, 2024
Debt [Abstract]
Debt	Note 8 – Debt Bank Credit Lines Bank credit lines consisted of the following: September 28, December 30, 2024 2023 Revolving credit agreement $ 50 $ 200 Other short-term bank credit lines 588 64 Total $ 638 $ 264 Revolving Credit Agreement On August 20, 2021 , we entered into a $ 1.0 which was subsequently amended and restated on July 11, 2023 July 11, 2028 update the interest rate provisions to reflect the current market approach rate on this revolving credit facility is based on Term Secured Overnight Financing Rate (“Term SOFR”) plus a spread based on our leverage ratio at the end of each financial reporting interest rate on this revolving credit facility was 4.96 % plus 1.18 % for a combined rate of 6.14 %. 30, 2023 the interest rate on this revolving credit facility was 5.36 % plus 1.00 % for a combined rate of 6.36 %. The Revolving Credit Agreement requires, among other things, that we Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated significant corporate changes (including mergers), dispositions and certain restrictive 28, 2024 and December 30, 2023, we had $ 50 200 revolving credit facility. the Revolving Credit Agreement was approximately $ 64 2023, there were $ 11 10 Revolving Credit Agreement. Other Short-Term Bank Credit As of September 28, 2024 and December 30, 2023, we had various other various currencies, with a maximum borrowing capacity of $ 689 368 September 28, 2024 and December 30, 2023, $ 588 64 the nine months ended September 28, 2024, the average outstanding balances bank credit lines was approximately $ 426 under other short-term bank credit lines had weighted average interest 5.94 % and 6.02 %, respectively. Long-term debt Long-term debt consisted of the following: September 28, December 30, 2024 2023 Private placement facilities $ 1,024 $ 1,074 Term loan 722 741 U.S. trade accounts receivable securitization 210 210 Various in varying installments through 2031 at interest rates from 0.00 % to 9.42 % at September 28, 2024 and from 0.00 % to 9.42 % at December 30, 2023 52 54 Finance lease obligations 7 8 Total 2,015 2,087 Less current maturities (109) (150) Total long-term debt $ 1,906 $ 1,937 Private Placement Facilities Our private placement facilities provided by four 1.5 and are available on an uncommitted basis at fixed rate economic terms from time to time through October 20, 2026 . at a fixed rate based on an agreed upon spread over applicable treasury each possible issuance will be selected by us and can range from five 15 years than 12 including working capital and capital expenditures, to refinance existing acquisitions. contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, changes in ownership. prior to the applicable due dates. The components of our private placement facility borrowings, which 3.66 %, as of September 28, 2024 are presented in the following table: Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date December 24, 2012 $ 50 3.00 % December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,024 Term Loan On July 11, 2023, we entered into a three-year 750 Agreement”). Term SOFR ratio at the end of each financial reporting quarter. July 11, 2026 . make quarterly payments of $ 9 July 2026. 5 through June 2024. 722 At September 28, 2024, the interest rate under the Term Credit Agreement was 5.10 % plus 1.60 % for a combined rate of 6.70 %. 741 December 30, 2023, the interest rate under the Term Credit Agreement was 5.36 % plus 1.35 % for a combined rate of 6.71 %. 6.04 % and 5.79 % at September 28, 2024 and December 30, 2023, respectively. things, that we maintain certain maximum leverage ratios. customary representations, warranties and affirmative covenants as well as customary to negotiated exceptions, on liens, indebtedness, significant corporate changes certain restrictive agreements. U.S. Trade Accounts Receivable Securitization We have a facility agreement based on our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . $ 450 two December 15, 2025 . As of September 28, 2024 and December 30, 2023, the borrowings were $ 210 210 this facility was based on the asset-backed commercial paper rate 5.28 % plus 0.75 %, for a combined rate of 6.03 %. commercial paper rate of 5.67 % plus 0.75 %, for a combined rate of 6.42 %. If our accounts receivable collection pattern changes due to customers our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 35

Income Taxes

Income Taxes	9 Months Ended
	Sep. 28, 2024
Income Taxes [Abstract]
Income Taxes	Note 9 – Income Taxes For the nine months ended September 28, 2024 our effective tax rate was 25.1 %, compared to 22.5 % for the prior year period. and foreign income taxes and interest expense. The Organization of Economic Co-Operation and Development (OECD) issued guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. rate is 15% for various jurisdictions pursuant to the Pillar Two rules. Pillar Two rules to our financial statements was immaterial. Pillar Two, Future tax reform resulting from these developments may result in changes may adversely impact our effective tax rate going forward or result in higher cash The total amount of unrecognized tax benefits, which are included in consolidated balance sheets, as of September 28, 2024 and December 30, 107 115 respectively, of which $ 99 107 It is possible that the amount of unrecognized tax benefits will material impact on our condensed consolidated statements of income. All tax returns audited by the IRS are officially closed through 2020. IRS include years 2021 and forward. examination. The amount of tax interest expense included as a component of the provision 1 3 million for the nine months ended September 28, 2024 and September accrued interest is included in “other liabilities,” and was $ 18 16 of December 30, 2023. condensed consolidated financial statements.

Plans of Restructuring

Plans of Restructuring	9 Months Ended
	Sep. 28, 2024
Plans of Restructuring [Abstract]
Plans of Restructuring	Note 10 – Plans of Restructuring On August 1, 2022, we committed to a restructuring plan (the “2022 Plan”) BOLD+1 strategic plan, streamlining operations and other initiatives to been completed as of July 31, 2024. in connection with our 2022 Plan, we recorded restructuring costs of 12 11 During the nine months ended September 28, 2024 and September 30, 2023, recorded restructuring costs of $ 37 59 primarily related to severance and employee-related costs, accelerated amortization fixed assets, and other exit costs. remainder of 2024. On August 6, 2024, we committed to a new restructuring plan (the “2024 right-size operations and further increase efficiencies. 2024, we recorded restructuring charges associated with the 2024 Plan of $ 36 severance and employee-related costs, accelerated amortization of right-of-use other lease exit costs. quarter of 2024 and in 2025, however an estimate of the amount of these charges has not Restructuring costs recorded for the three and nine months ended September connection with the 2022 Plan and 2024 Plan consisted of the following: Three Months Ended Nine Months Ended Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total 2024 Plan Severance and employee-related costs $ 26 $ 5 $ 31 $ 26 $ 5 $ 31 Accelerated depreciation and amortization 2 2 4 2 2 4 Exit and other related costs 1 - 1 1 - 1 Restructuring costs-2024 Plan $ 29 $ 7 $ 36 $ 29 $ 7 $ 36 2022 Plan Severance and employee-related costs $ 7 $ 1 $ 8 $ 21 $ 3 $ 24 Accelerated depreciation and amortization 1 - 1 7 - 7 Exit and other related costs 1 2 3 4 2 6 Restructuring costs-2022 Plan $ 9 $ 3 $ 12 $ 32 $ 5 $ 37 Total restructuring $ 38 $ 10 $ 48 $ 61 $ 12 $ 73 Three Months Ended Nine Months Ended Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total 2022 Plan Severance and employee-related costs $ 6 $ - $ 6 $ 36 $ 4 $ 40 Accelerated depreciation and amortization 3 1 4 12 2 14 Exit and other related costs 1 - 1 3 1 4 Loss on disposal of a business - - - 1 - 1 Total restructuring $ 10 $ 1 $ 11 $ 52 $ 7 $ 59 The following table summarizes, initiatives under the 2022 Plan and the 2024 Plan for the nine months accrued balance of restructuring costs as of September 28, 2024, which employee-related costs, is included in accrued expenses: other within Liabilities related to exited leased facilities are recorded within our current liabilities within our condensed consolidated balance sheets. 2022 Plan 2024 Plan Total Balance, December 30, 2023 $ 23 $ - $ 23 Restructuring costs 37 36 73 Non-cash accelerated depreciation and amortization (7) (4) (11) Cash payments and other adjustments (35) (7) (42) Balance, September 28, 2024 $ 18 $ 25 $ 43

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 28, 2024
Legal Proceedings [Abstract]
Legal Proceedings	Note 11 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid hundred and seventy-five ( 175 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). in a false advertising campaign to expand the market for such drugs and in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped otherwise failing to monitor appropriately and restrict the improper distribution consist of some that have been consolidated within the MultiDistrict Litigation Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) remain pending in state courts and are proceeding independently and outside following case is set for trial: the action filed by Florida Health Sciences Center, Inc. (and 25 other hospitals located throughout the State of Florida) in Florida state court, which is currently 2025. 12.3 four - tenths of 1 percent. against these actions. In August 2022, Henry Schein received a Grand Jury Subpoena from the United Western District of Virginia, Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. October 2022, Henry Schein received a second Grand Jury Subpoena the Western District of Virginia. received from Butler or Covetrus, Inc. (“Covetrus”). subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. investigation. On January 18, 2024, a putative class action was filed against the Company Eastern District of New York (“EDNY”), Case No. 24-cv-387 (the “Cruz-Bermudez Action”), based on the October 2023 cyber incident described in On January 26, 2024, a second putative class action was filed against the Company based on the cyber incident, also “Depperschmidt Action”). prejudice. plaintiffs’ counsel from the Depperschmidt Action and an additional new plaintiff. Plaintiffs in the Cruz-Bermudez Action seek to represent a class of all individuals information and personal health information was compromised by been harmed by alleged actions and/or omissions by the Company Company made deceptive public statements regarding privacy and data protection. claims seeking monetary damages, injunctive relief, costs and attorneys’ 22, 2024, plaintiffs voluntarily withdrew two of their five causes of action. Company’s motion to dismiss the remaining claims. On June 6, 2024, plaintiffs and the Company informed the court that they had agreed action settlement of the Cruz-Bermudez Action. agreement on September 13, 2024, and the court preliminarily approved 2024. Cruz-Bermudez Action will be terminated, the Company will receive Company will pay $ 2.9 final approval. Henry Schein, Inc. and its subsidiary, North American Rescue, LLC (“NAR”), were named as defendants in a qui tam lawsuit brought under the federal False Claims Act (“FCA”), Russ and Murphy ex rel. United States v. North American Rescue, LLC et al. ; Case No. 21-cv-04238, filed in the United States District for the Eastern District of Pennsylvania. Chris Murphy) who worked for one of NAR’s competitors. as a defendant. “CAT”). amended complaint in November 2023. R, Relators requested and obtained leave to file their Second Amended 2024, the court ruled on motions to dismiss filed by Henry Schein, claims against Henry Schein (without prejudice). denied. connection with, and sold and submitted false claims for payment to the federal products that Relators contend violated certain “Buy American” Agreements Act of 1979) and/or were not properly sterilized as noted misbranded. blankets, eye, ear, nose and throat kits, and trauma dressing. be proved at trial, statutory civil penalties, reasonable expenses, attorneys’ interest. From time to time, we may become a party to other legal proceedings, liability claims, employment matters, commercial disputes, governmental in some cases involve our entering into settlement arrangements or consent of the ordinary course of our business. in our opinion none of these other pending matters are currently consolidated financial position, liquidity or results of operations. As of September 28, 2024, we had accrued our best estimate of potential losses probable to result in liability and for which we were able to reasonably well as related expenses, was not material to our financial position, for determining estimated losses considers currently available facts, other factors, including probable recoveries from third parties.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 28, 2024
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 12 – Stock-Based Compensation Stock-based awards are provided to certain employees under our 2024 Stock Incentive 2020 Stock Incentive Plan) and to non-employee directors under our 2023 Non-Employee Plan (together, the “Plans”). (the “Compensation Committee”). the form of time-based and performance-based restricted stock units (“RSUs”) with year in which non-qualified stock options were issued in place of performance-based granted time-based and performance-based RSUs, as well as non-qualified plan year, performance-based RSUs. based RSUs. RSUs are stock-based awards granted to recipients with specified vesting provisions. stock is delivered on or following satisfaction of vesting conditions. vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. 12 -month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line For all RSUs, we estimate the fair value based on our closing stock performance-based RSUs, the number of shares that ultimately vest and our performance as measured against specified targets over a specified period, as Committee. performance-based RSUs based on our closing stock price at time of grant. Each of the Plans provide for certain adjustments to the performance the Plans. performance measurement adjustments relate to significant events, including, divestitures, new business ventures, certain capital transactions (including share budgeted average outstanding shares (other than those resulting from capital restructuring costs, if any, amortization expense recorded for acquisition-related intangible assets (solely with respect to performance-based RSUs granted in the 2023 and 2024 plan years), payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact in projected earnings generated by COVID-19 test kits (solely with respect the 2022 and 2023 plan years) and impairment charges (solely with respect to performance-based the 2023 and 2024 plan years), and unforeseen events or circumstances Over the performance period, the number of RSUs that will ultimately vest compensation expense is adjusted upward or downward based upon our targets. expense is based on our actual performance against the pre-determined performance adjusted). Stock options are awards that allow the recipient to purchase shares of our price set at the time of grant. date of grant. one-third service, subject to the terms and conditions of the 2020 Stock Incentive Plan, three years grant date and have a contractual term of ten years term acceleration upon certain events. vesting method. During the nine months ended September 28, 2024, we did no t grant any stock options. Our condensed consolidated statements of income reflect pre-tax share-based compensation 10 and $ 30 months ended September 30, 2023, we recorded pre-tax share-based compensation 14 38 million. Total unrecognized compensation cost related to unvested awards as of September 28, 2024 was $ 83 is expected to be recognized over a weighted-average period of approximately 2.6 Our condensed consolidated statements of cash flows present our reconciling adjustment between net income and net cash provided by operating There were no cash benefits associated with tax deductions in excess of months ended September 28, 2024 and September 30, 2023. The following table summarizes the stock option activity for the nine months Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Shares Price Life (in years) Outstanding at beginning of period 1,078,459 $ 71.46 Granted - Exercised (48,842) 62.71 Forfeited (10,980) 85.31 Outstanding at end of period 1,018,637 $ 71.73 6.8 $ 6 Options exercisable at end of period 887,589 $ 69.70 Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Expected to vest 131,048 $ 85.51 7.5 $ - The following tables summarize the activity of our unvested RSUs for Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Weighted Average Intrinsic Average Intrinsic Grant Date Fair Value Grant Date Fair Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,655,393 $ 70.34 208,742 $ 78.02 Granted 465,339 75.83 329,118 76.70 Vested (329,115) 63.00 (8,262) 66.53 Forfeited (87,304) 77.19 (55,976) 79.69 Outstanding at end of period 1,704,313 $ 72.92 $ 73.22 473,622 $ 75.91 $ 73.22

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	9 Months Ended
	Sep. 28, 2024
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 13 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, their ownership interest in those entities at fair value. applicable for noncontrolling interests where we are or may be required outstanding interest in a consolidated subsidiary from the noncontrolling option contained in contractual agreements. interests for the nine months ended September 28, 2024 and the year following table: September 28, December 30, 2024 2023 Balance, beginning of period $ 864 $ 576 Decrease in redeemable noncontrolling interests due to acquisitions of (257) (19) Increase in redeemable noncontrolling interests due to business acquisitions 172 326 Net income attributable to redeemable noncontrolling interests - 6 Distributions declared, net of capital contributions (30) (19) Effect of foreign currency translation gain (loss) attributable to (4) 5 Change in fair value of redeemable securities 87 (11) Balance, end of period $ 832 $ 864

Comprehensive Income

Comprehensive Income	9 Months Ended
	Sep. 28, 2024
Comprehensive Income [Abstract]
Comprehensive Income	Note 14 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income and are recorded directly to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of September 28, December 30, 2024 2023 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (36) $ (32) Attributable to noncontrolling interests: Foreign currency translation adjustment $ - $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (243) $ (188) Unrealized gain loss from hedging activities (16) (13) Pension adjustment loss (5) (5) Accumulated other comprehensive loss $ (264) $ (206) Total Accumulated $ (300) $ (239) The following table summarizes the components of comprehensive income, net Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Net income $ 99 $ 143 $ 302 $ 419 Foreign currency translation gain (loss) 58 (45) (58) (17) Tax effect - - - - Foreign currency translation gain (loss) 58 (45) (58) (17) Unrealized gain (loss) from hedging activities (25) 9 (4) 3 Tax effect 7 (3) 1 (1) Unrealized gain (loss) from hedging activities (18) 6 (3) 2 Comprehensive income $ 139 $ 104 $ 241 $ 404 Our financial statements are denominated in U.S. Dollars. compared to the U.S. Dollar may have a significant impact on our translation gain (loss) during the nine months ended September 28, 2024 and 2023 was primarily due to changes in foreign currency exchange Swiss Franc, Canadian Dollar, and Australian Dollar. The hedging gain (loss) during the three and nine months ended September attributable to a net investment hedge. The following table summarizes our total comprehensive income, net of Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Comprehensive income attributable to Henry Schein, Inc. $ 127 $ 100 $ 238 $ 384 Comprehensive income attributable to noncontrolling interests - 4 7 10 Comprehensive income (loss) attributable to Redeemable noncontrolling interests 12 - (4) 10 Comprehensive income $ 139 $ 104 $ 241 $ 404

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 28, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 15 Earnings Per Share Basic earnings per share is computed by dividing net income attributable average number of common shares outstanding for the period. to basic earnings per share, except that it reflects the effect of common shares issuable exercise of stock options using the treasury stock method in periods A reconciliation of shares used in calculating earnings per basic and Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Basic 126,124,715 130,388,353 127,550,045 130,888,717 Effect of dilutive securities: Stock options and restricted stock units 930,219 1,053,782 948,449 1,260,455 Diluted 127,054,934 131,442,135 128,498,494 132,149,172 The number of antidilutive securities that were excluded from the calculation shares outstanding are as follows: Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Stock options 412,574 424,005 416,065 426,237 Restricted stock units 17,627 7,362 16,339 15,072 Total anti-dilutive share computation 430,201 431,367 432,404 441,309

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 28, 2024
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 16 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Nine Months Ended September 28, September 30, 2024 2023 Interest $ 92 $ 52 Income taxes 127 178 For the nine months ended September 28, 2024 and September 30, 2023, we had (4) 3 non-cash net unrealized gains (losses) related to hedging activities,

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 28, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 17 – Related Party Transactions In connection with the formation of Henry Schein One, LLC, our joint venture formed on July 1, 2018, we entered into a ten-year Internet Brands approximately $ 31 nine months ended September 28, 2024, we recorded $ 8 23 general and administrative in our condensed consolidated statements of income, this royalty agreement. 8 $ 23 income, in connection with costs related to this royalty agreement. 2023, Henry Schein One, LLC had a net payable balance to Internet 10 1 respectively, comprised of amounts related to results of operations and the royalty agreement. this payable are recorded within accrued expenses: other within our condensed We have interests in entities that we account for under the equity accounting method. business, during the three and nine months ended September 28, 2024, we 14 $ 38 recorded net sales of $ 11 34 ended September 28, 2024, we purchased $ 2 8 three and nine months ended September 30, 2023, we purchased $ 1 7 entities. 32 32 respectively, due from our equity affiliates, and $ 8 5 Certain of our facilities related to our acquisitions are leased from employees leases are classified as operating leases and have a remaining lease term six months 13 of September 28, 2024, current and non-current liabilities associated with related 6 million and $ 22 7.4 % and 8.3 % of the total current and non-current operating lease liabilities, respectively. current liabilities associated with related party operating leases were $ 5 23 December 30, 2023, related party leases represented 6.3 % and 7.4 % of the total current and non-current operating lease liabilities, respectively.

Basis of Presentation (Policy)

Basis of Presentation (Policy)	9 Months Ended
	Sep. 28, 2024
Basis of Presentation [Abstract]
Principles of Consolidation	Our condensed consolidated financial statements include the accounts of Henry controlled subsidiaries (“we”, “us” and “our”). consolidation. financial decisions are accounted for under the equity method. to conform to the current period presentation. have a material impact on our condensed consolidated financial condition,
Use of Estimates	The preparation of financial statements in conformity with accounting principles States requires us to make estimates and assumptions that affect the reported amounts of disclosure of contingent assets and liabilities at the date of the financial revenues and expenses during the reporting period. operations for the three and nine months ended September 28, 2024 be expected for any other interim period or for the year ending December 28, 2024.
Consolidated Variable Interest Entity	We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the benefits. debt. and December 30, 2023, certain trade accounts receivable that can were $ 341 284 to us were $ 210 210

Significant Accounting Polici_2

Significant Accounting Policies and Recently Issued Accounting Standards (Policy)	9 Months Ended
	Sep. 28, 2024
Significant Accounting Policies and Recently Issued Accounting Standards [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-01, “ Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, ” which clarifies how to determine whether profits interest and for as a share-based payment arrangement under Topic 718 or within the scope of other guidance. provides an illustrative example with multiple fact patterns and amends Topic 718 to improve its clarity and operability. profits interest awards as compensation to employees or nonemployees can apply the amendments either retrospectively to all periods presented to profits interest awards granted or modified on or after the date an entity must disclose the nature of and reason for the change in accounting principle adoption of the ASU. periods within those fiscal years. impact on our consolidated financial statements. In December 2023, FASB issued ASU 2023-09, “ Income Taxes (Topic Disclosures ,” which requires public business entities to disclose additional respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and It also requires greater detail about individual reconciling items in those items exceeds a specified threshold. ASU requires information pertaining to taxes paid (net of refunds received) and foreign taxes and further disaggregated for specific jurisdictions quantitative threshold. determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event triggered the establishment of the reconciling item and the activity with which The ASU eliminates the historic requirement that entities disclose information benefits having a reasonable possibility of significantly increasing reporting date. permitted for annual financial statements that have not yet been should be applied on a prospective basis; however, retrospective application is permitted. evaluating the impact that ASU 2023-09 will have on our consolidated In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segments ,” which aims to improve financial reporting by requiring disclosure on an annual and interim basis for all public entities to enable investors to analyses. segments. operating decision maker uses to assess segment performance and Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization and depletion expense, to be disclosed under certain circumstances. remove those disclosure requirements and do not change how a public aggregates those operating segments or applies the quantitative thresholds This ASU is effective for fiscal years beginning after December 15, 2023, and interim beginning after December 15, 2024. 2023- 07 will have on our consolidated financial statements.

Net Sales from Contracts with_2

Net Sales from Contracts with Customers (Tables)	9 Months Ended
	Sep. 28, 2024
Net Sales from Contracts with Customers [Abstract]
Disaggregation of Revenue	Three Months Ended Nine Months Ended September 28, 2024 September 28, 2024 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,089 $ 763 $ 1,852 $ 3,321 $ 2,369 $ 5,690 Medical 1,076 25 1,101 3,060 80 3,140 Total health care distribution 2,165 788 2,953 6,381 2,449 8,830 Technology 190 31 221 565 87 652 Total net sales $ 2,355 $ 819 $ 3,174 $ 6,946 $ 2,536 $ 9,482 Three Months Ended Nine Months Ended September 30, 2023 September 30, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,134 $ 748 $ 1,882 $ 3,447 $ 2,290 $ 5,737 Medical 1,044 26 1,070 2,920 71 2,991 Total health care distribution 2,178 774 2,952 6,367 2,361 8,728 Technology 185 25 210 519 75 594 Total net sales $ 2,363 $ 799 $ 3,162 $ 6,886 $ 2,436 $ 9,322

Segment Data (Tables)

Segment Data (Tables)	9 Months Ended
	Sep. 28, 2024
Segment Data [Abstract]
Business Segment Information	Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Net sales: Health care distribution (1) Dental $ 1,852 $ 1,882 $ 5,690 $ 5,737 Medical 1,101 1,070 3,140 2,991 Total health care distribution 2,953 2,952 8,830 8,728 Technology (2) 221 210 652 594 Total $ 3,174 $ 3,162 $ 9,482 $ 9,322 Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Operating Income: Health care distribution $ 118 $ 160 $ 390 $ 471 Technology 39 40 76 105 Total $ 157 $ 200 $ 466 $ 576

Business Acquisitions (Tables)

Business Acquisitions (Tables)	9 Months Ended
	Sep. 28, 2024
TriMed, Inc. [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2024 Acquisition consideration: Cash $ 141 Deferred consideration 22 Redeemable noncontrolling interests 153 Total consideration $ 316 Identifiable assets acquired and liabilities assumed: Current assets $ 36 Intangible assets 221 Other noncurrent assets 10 Current liabilities (9) Deferred income taxes (62) Other noncurrent liabilities (6) Total identifiable 190 Goodwill 126 Total net assets acquired $ 316
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2024 Weighted Average Lives (in years) Product development $ 204 9 Trademarks / Tradenames 9 7 In process research & development 8 Not Applicable Total $ 221
Shield Healthcare, Inc. [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	Final Allocation Acquisition consideration: Cash $ 289 Deferred consideration 22 Redeemable noncontrolling interests 37 Total consideration $ 348 Identifiable assets acquired and liabilities assumed: Current assets $ 41 Intangible assets 166 Other noncurrent assets 16 Current liabilities (24) Deferred income taxes (43) Other noncurrent liabilities (7) Total identifiable 149 Goodwill 199 Total net assets acquired $ 348
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Weighted Average (in years) Customer relationships and lists $ 156 12 Trademarks / Tradenames 10 5 Total $ 166
S.I.N [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	Final Allocation Acquisition consideration: Cash $ 329 Total consideration $ 329 Identifiable assets acquired and liabilities assumed: Current assets $ 73 Intangible assets 87 Other noncurrent assets 48 Current liabilities (33) Long-term debt (22) Deferred income taxes (38) Other noncurrent liabilities (27) Total identifiable 88 Goodwill 241 Total net assets acquired $ 329
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Weighted Average (in years) Customer relationships and lists $ 38 7 Product development 36 8 Trademarks / Tradenames 13 10 Total $ 87
Biotech Dental [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	Final Allocation Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 74 Intangible assets 189 Other noncurrent assets 69 Current liabilities (60) Long-term debt (73) Deferred income taxes (53) Other noncurrent liabilities (20) Total identifiable 126 Goodwill 297 Total net assets acquired $ 423
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Weighted Average Lives (in years) Product development $ 124 10 Customer relationships and lists 47 9 Trademarks / Tradenames 18 7 Total $ 189

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 28, 2024
Fair Value Measurements [Abstract]
Assets and Liabilities Measured and Recognized on a Recurring Basis	September 28, 2024 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ - $ - $ - Derivative contracts undesignated - 2 - 2 Total return - 2 - 2 Total assets $ - $ 4 $ - $ 4 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 3 - 3 Contingent consideration - - 49 49 Total liabilities $ - $ 21 $ 49 $ 70 Redeemable noncontrolling interests $ - $ - $ 832 $ 832 December 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total return - 4 - 4 Total assets $ - $ 6 $ - $ 6 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 20 $ - $ 20 Redeemable noncontrolling interests $ - $ - $ 864 $ 864

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 28, 2024
Debt [Abstract]
Schedule of Bank Credit Lines	September 28, December 30, 2024 2023 Revolving credit agreement $ 50 $ 200 Other short-term bank credit lines 588 64 Total $ 638 $ 264
Schedule of Long-Term Debt	September 28, December 30, 2024 2023 Private placement facilities $ 1,024 $ 1,074 Term loan 722 741 U.S. trade accounts receivable securitization 210 210 Various in varying installments through 2031 at interest rates from 0.00 % to 9.42 % at September 28, 2024 and from 0.00 % to 9.42 % at December 30, 2023 52 54 Finance lease obligations 7 8 Total 2,015 2,087 Less current maturities (109) (150) Total long-term debt $ 1,906 $ 1,937
Schedule of Private Placement Facility Borrowings	Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date December 24, 2012 $ 50 3.00 % December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,024

Plans of Restructuring (Tables)

Plans of Restructuring (Tables)	9 Months Ended
	Sep. 28, 2024
Plans of Restructuring [Abstract]
Schedule of Restructuring Costs	Three Months Ended Nine Months Ended Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total 2024 Plan Severance and employee-related costs $ 26 $ 5 $ 31 $ 26 $ 5 $ 31 Accelerated depreciation and amortization 2 2 4 2 2 4 Exit and other related costs 1 - 1 1 - 1 Restructuring costs-2024 Plan $ 29 $ 7 $ 36 $ 29 $ 7 $ 36 2022 Plan Severance and employee-related costs $ 7 $ 1 $ 8 $ 21 $ 3 $ 24 Accelerated depreciation and amortization 1 - 1 7 - 7 Exit and other related costs 1 2 3 4 2 6 Restructuring costs-2022 Plan $ 9 $ 3 $ 12 $ 32 $ 5 $ 37 Total restructuring $ 38 $ 10 $ 48 $ 61 $ 12 $ 73 Three Months Ended Nine Months Ended Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total 2022 Plan Severance and employee-related costs $ 6 $ - $ 6 $ 36 $ 4 $ 40 Accelerated depreciation and amortization 3 1 4 12 2 14 Exit and other related costs 1 - 1 3 1 4 Loss on disposal of a business - - - 1 - 1 Total restructuring $ 10 $ 1 $ 11 $ 52 $ 7 $ 59
Schedule of Restructuring Reserve by Segment	2022 Plan 2024 Plan Total Balance, December 30, 2023 $ 23 $ - $ 23 Restructuring costs 37 36 73 Non-cash accelerated depreciation and amortization (7) (4) (11) Cash payments and other adjustments (35) (7) (42) Balance, September 28, 2024 $ 18 $ 25 $ 43

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 28, 2024
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Shares Price Life (in years) Outstanding at beginning of period 1,078,459 $ 71.46 Granted - Exercised (48,842) 62.71 Forfeited (10,980) 85.31 Outstanding at end of period 1,018,637 $ 71.73 6.8 $ 6 Options exercisable at end of period 887,589 $ 69.70
Intrinsic Values	Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Expected to vest 131,048 $ 85.51 7.5 $ -
Status of Unvested RSUs	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Weighted Average Intrinsic Average Intrinsic Grant Date Fair Value Grant Date Fair Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,655,393 $ 70.34 208,742 $ 78.02 Granted 465,339 75.83 329,118 76.70 Vested (329,115) 63.00 (8,262) 66.53 Forfeited (87,304) 77.19 (55,976) 79.69 Outstanding at end of period 1,704,313 $ 72.92 $ 73.22 473,622 $ 75.91 $ 73.22

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interests (Tables)	9 Months Ended
	Sep. 28, 2024
Redeemable Noncontrolling Interests [Abstract]
Components of the Change in Redeemable Noncontrolling Interests	September 28, December 30, 2024 2023 Balance, beginning of period $ 864 $ 576 Decrease in redeemable noncontrolling interests due to acquisitions of (257) (19) Increase in redeemable noncontrolling interests due to business acquisitions 172 326 Net income attributable to redeemable noncontrolling interests - 6 Distributions declared, net of capital contributions (30) (19) Effect of foreign currency translation gain (loss) attributable to (4) 5 Change in fair value of redeemable securities 87 (11) Balance, end of period $ 832 $ 864

Comprehensive Income (Tables)

Comprehensive Income (Tables)	9 Months Ended
	Sep. 28, 2024
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss Net of Applicable Taxes	September 28, December 30, 2024 2023 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (36) $ (32) Attributable to noncontrolling interests: Foreign currency translation adjustment $ - $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (243) $ (188) Unrealized gain loss from hedging activities (16) (13) Pension adjustment loss (5) (5) Accumulated other comprehensive loss $ (264) $ (206) Total Accumulated $ (300) $ (239)
Components of Comprehensive Income, Net of Applicable Taxes	Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Net income $ 99 $ 143 $ 302 $ 419 Foreign currency translation gain (loss) 58 (45) (58) (17) Tax effect - - - - Foreign currency translation gain (loss) 58 (45) (58) (17) Unrealized gain (loss) from hedging activities (25) 9 (4) 3 Tax effect 7 (3) 1 (1) Unrealized gain (loss) from hedging activities (18) 6 (3) 2 Comprehensive income $ 139 $ 104 $ 241 $ 404
Total Comprehensive Income, Net of Applicable Taxes	Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Comprehensive income attributable to Henry Schein, Inc. $ 127 $ 100 $ 238 $ 384 Comprehensive income attributable to noncontrolling interests - 4 7 10 Comprehensive income (loss) attributable to Redeemable noncontrolling interests 12 - (4) 10 Comprehensive income $ 139 $ 104 $ 241 $ 404

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 28, 2024
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Basic 126,124,715 130,388,353 127,550,045 130,888,717 Effect of dilutive securities: Stock options and restricted stock units 930,219 1,053,782 948,449 1,260,455 Diluted 127,054,934 131,442,135 128,498,494 132,149,172
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended Nine Months Ended September 28, September 30, September 28, September 30, 2024 2023 2024 2023 Stock options 412,574 424,005 416,065 426,237 Restricted stock units 17,627 7,362 16,339 15,072 Total anti-dilutive share computation 430,201 431,367 432,404 441,309

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 28, 2024
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Nine Months Ended September 28, September 30, 2024 2023 Interest $ 92 $ 52 Income taxes 127 178

Basis of Presentation - Narrati

Basis of Presentation - Narrative (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Asset Pledged as Collateral [Member]
Pledged assets	$ 341	$ 284
Recourse [Member]
Liabilities of VIE	$ 210	$ 210

Cybersecurity Incident - Narrat

Cybersecurity Incident - Narrative (Details) - Cyber Incident [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 28, 2024	Sep. 28, 2024
Unusual or Infrequent Item, or Both [Line Items]
Expenses related to cybersecurity incident	$ 1	$ 9
Insurance proceeds related to cybersecurity incident	$ 10	20
Insurance policy limitations		60
Insurance retention		$ 5

Net Sales from Contracts with_3

Net Sales from Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Contract with Customer, Liability, Current	$ 76		$ 89	$ 86
Contract with Customer, Liability, Noncurrent	8		$ 9	$ 8
Contract with Customer, Liability, Revenue Recognized	$ 72	$ 70

Net Sales from Contracts with_4

Net Sales from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Disaggregation of Revenue [Abstract]
Net sales	$ 3,174	$ 3,162	$ 9,482	$ 9,322
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,355	2,363	6,946	6,886
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	819	799	2,536	2,436
Health Care Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,953	2,952	8,830	8,728
Health Care Distribution [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,165	2,178	6,381	6,367
Health Care Distribution [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	788	774	2,449	2,361
Health Care Distribution [Member] | Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,852	1,882	5,690	5,737
Health Care Distribution [Member] | Dental [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,089	1,134	3,321	3,447
Health Care Distribution [Member] | Dental [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	763	748	2,369	2,290
Health Care Distribution [Member] | Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,101	1,070	3,140	2,991
Health Care Distribution [Member] | Medical [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,076	1,044	3,060	2,920
Health Care Distribution [Member] | Medical [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	25	26	80	71
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	221	210	652	594
Technology and Value-Added Services [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	190	185	565	519
Technology and Value-Added Services [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 31	$ 25	$ 87	$ 75

Segment Data (Details)

Segment Data (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024 USD ($) countries	Sep. 30, 2023 USD ($)	Sep. 28, 2024 USD ($) segments countries	Sep. 30, 2023 USD ($)
Segment Data [Abstract]
Number of reportable segments | segments			2
Segment Reporting Information [Line Items]
Net sales	$ 3,174	$ 3,162	$ 9,482	$ 9,322
Operating income	157	200	466	576
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	2,953	2,952	8,830	8,728
Operating income	$ 118	160	$ 390	471
Number of countries served globally | countries	33		33
Health Care Distribution [Member] | Dental [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,852	1,882	$ 5,690	5,737
Health Care Distribution [Member] | Medical [Member]
Segment Reporting Information [Line Items]
Net sales	1,101	1,070	3,140	2,991
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	221	210	652	594
Operating income	$ 39	$ 40	$ 76	$ 105

Business Acquisitions - Narrati

Business Acquisitions - Narrative (Details) - USD ($) $ in Millions

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Apr. 01, 2024

Oct. 02, 2023

Jul. 05, 2023

Apr. 05, 2023

Sep. 28, 2024

Sep. 30, 2023

Sep. 28, 2024

Sep. 28, 2024

Jun. 29, 2024

Sep. 30, 2023

Jun. 29, 2024

Mar. 30, 2024

Dec. 30, 2023

Business Acquisition [Line Items]

Goodwill

$ 3,986

$ 3,986

$ 3,986

$ 3,875

Acquisition costs incurred

2

$ 6

5

$ 18

TriMed, Inc. [Member]

Business Acquisition [Line Items]

Percentage of voting interest acquired

60%

Total consideration

$ 316

Consideration paid

141

Deferred consideration

22

Redeemable noncontrolling interests

153

Goodwill

126

Intangible assets

$ 221

TriMed, Inc. [Member] | Product Development [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

9 years

TriMed, Inc. [Member] | Trademarks And Trade Names [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

7 years

Shield Healthcare, Inc. [Member]

Business Acquisition [Line Items]

Percentage of voting interest acquired

90%

Total consideration

$ 348

$ 348

Consideration paid

289

289

Deferred consideration

22

22

Redeemable noncontrolling interests

$ 37

37

Goodwill

199

$ 199

Intangible assets

$ 166

166

Shield Healthcare, Inc. [Member] | Customer Relationships and Lists [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

12 years

Shield Healthcare, Inc. [Member] | Trademarks And Trade Names [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

5 years

S.I.N. Implant System [Member]

Business Acquisition [Line Items]

Percentage of voting interest acquired

100%

Total consideration

$ 329

329

Consideration paid

329

Goodwill

$ 241

241

Intangible assets

$ 87

$ 87

S.I.N. Implant System [Member] | Customer Relationships and Lists [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

7 years

S.I.N. Implant System [Member] | Product Development [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

8 years

S.I.N. Implant System [Member] | Trademarks And Trade Names [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

10 years

Biotech Dental [Member]

Business Acquisition [Line Items]

Percentage of voting interest acquired

57%

Total consideration

$ 423

$ 423

Consideration paid

216

216

Fair value of contributed equity share in a controlled subsidiary

25

25

Redeemable noncontrolling interests

$ 182

182

Goodwill

297

Intangible assets

$ 189

Biotech Dental [Member] | Customer Relationships and Lists [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

9 years

Biotech Dental [Member] | Product Development [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

10 years

Biotech Dental [Member] | Trademarks And Trade Names [Member]

Business Acquisition [Line Items]

Estimated useful lives (in years)

7 years

Series Of Individually Immaterial Business Acquisitions [Member]

Business Acquisition [Line Items]

Total consideration

113

Goodwill

59

$ 59

59

Intangible assets

64

64

64

Recognized gain related to remeasurement to fair value of previously held equity investment

19

19

Series Of Individually Immaterial Business Acquisitions [Member] | Customer Relationships and Lists [Member]

Business Acquisition [Line Items]

Intangible assets

33

33

$ 33

Estimated useful lives (in years)

11 years

Series Of Individually Immaterial Business Acquisitions [Member] | Product Development [Member]

Business Acquisition [Line Items]

Intangible assets

5

5

$ 5

Estimated useful lives (in years)

9 years

Series Of Individually Immaterial Business Acquisitions [Member] | Non-compete Agreements [Member]

Business Acquisition [Line Items]

Intangible assets

2

2

$ 2

Estimated useful lives (in years)

5 years

Series Of Individually Immaterial Business Acquisitions [Member] | Trademarks And Trade Names [Member]

Business Acquisition [Line Items]

Intangible assets

$ 24

$ 24

$ 24

Estimated useful lives (in years)

7 years

Series Of Individually Immaterial Business Acquisitions [Member] | Minimum [Member]

Business Acquisition [Line Items]

Percentage of voting interest acquired

51%

51%

51%

51%

Series Of Individually Immaterial Business Acquisitions [Member] | Maximum [Member]

Business Acquisition [Line Items]

Percentage of voting interest acquired

100%

100%

100%

100%

Other 2023 Acquisitions [Member]

Business Acquisition [Line Items]

Change in fair value of contingent consideration

$ 0

$ 38

Business Acquisitions - Summary

Business Acquisitions - Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired (Details) - USD ($) $ in Millions					9 Months Ended	12 Months Ended
	Apr. 01, 2024	Oct. 02, 2023	Jul. 05, 2023	Apr. 05, 2023	Jun. 29, 2024	Jun. 29, 2024	Mar. 30, 2024	Sep. 28, 2024	Dec. 30, 2023
Identifiable assets acquired and liabilities assumed:
Goodwill								$ 3,986	$ 3,875
TriMed, Inc. [Member]
Acquisition consideration:
Cash	$ 141
Deferred consideration	22
Redeemable noncontrolling interests	153
Total consideration	316
Identifiable assets acquired and liabilities assumed:
Current assets	36
Intangible assets	221
Other noncurrent assets	10
Current liabilities	(9)
Deferred income taxes	(62)
Other noncurrent liabilities	(6)
Total identifiable net assets	190
Goodwill	126
Total net assets acquired	$ 316
Shield Healthcare, Inc. [Member]
Acquisition consideration:
Cash		$ 289			$ 289
Deferred consideration		22			22
Redeemable noncontrolling interests		37			37
Total consideration		$ 348			348
Identifiable assets acquired and liabilities assumed:
Current assets					41	$ 41
Intangible assets					166	166
Other noncurrent assets					16	16
Current liabilities					(24)	(24)
Deferred income taxes					(43)	(43)
Other noncurrent liabilities					(7)	(7)
Total identifiable net assets					149	149
Goodwill					199	199
Total net assets acquired					348	348
S.I.N. Implant System [Member]
Acquisition consideration:
Cash						329
Total consideration			$ 329			329
Identifiable assets acquired and liabilities assumed:
Current assets					73	73
Intangible assets					87	87
Other noncurrent assets					48	48
Current liabilities					(33)	(33)
Long-term debt					(22)	(22)
Deferred income taxes					(38)	(38)
Other noncurrent liabilities					(27)	(27)
Total identifiable net assets					88	88
Goodwill					241	241
Total net assets acquired					$ 329	$ 329
Biotech Dental [Member]
Acquisition consideration:
Cash				$ 216			$ 216
Fair value of contributed equity share in a controlled subsidiary				25			25
Redeemable noncontrolling interests				182			182
Total consideration				$ 423			423
Identifiable assets acquired and liabilities assumed:
Current assets							74
Intangible assets							189
Other noncurrent assets							69
Current liabilities							(60)
Long-term debt							(73)
Deferred income taxes							(53)
Other noncurrent liabilities							(20)
Total identifiable net assets							126
Goodwill							297
Total net assets acquired							$ 423

Business Acquisitions - Summa_2

Business Acquisitions - Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives (Details) - USD ($) $ in Millions		6 Months Ended	9 Months Ended	12 Months Ended
	Jul. 05, 2023	Sep. 28, 2024	Jun. 29, 2024	Jun. 29, 2024	Mar. 30, 2024
TriMed, Inc. [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 221
TriMed, Inc. [Member] | Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 204
Estimated useful lives (in years)		9 years
TriMed, Inc. [Member] | Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 9
Estimated useful lives (in years)		7 years
TriMed, Inc. [Member] | In Process Research And Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 8
Shield Healthcare, Inc. [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 166
Shield Healthcare, Inc. [Member] | Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 156
Estimated useful lives (in years)			12 years
Shield Healthcare, Inc. [Member] | Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 10
Estimated useful lives (in years)			5 years
S.I.N. Implant System [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				$ 87
S.I.N. Implant System [Member] | Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				38
Estimated useful lives (in years)	7 years
S.I.N. Implant System [Member] | Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				36
Estimated useful lives (in years)	8 years
S.I.N. Implant System [Member] | Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				$ 13
Estimated useful lives (in years)	10 years
Biotech Dental [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired					$ 189
Biotech Dental [Member] | Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired					$ 47
Estimated useful lives (in years)					9 years
Biotech Dental [Member] | Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired					$ 124
Estimated useful lives (in years)					10 years
Biotech Dental [Member] | Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired					$ 18
Estimated useful lives (in years)					7 years

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt (including bank credit lines)	$ 2,653	$ 2,351

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured and Recognized on a Recurring Basis (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023	Dec. 31, 2022
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 832	$ 864	$ 576
Fair value, measurements, recurring [Member]
Assets [Abstract]
Total return swaps	2	4
Total assets	4	6
Liabilities [Abstract]
Contingent consideration	49
Total liabilities	70	20
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	832	864
Fair value, measurements, recurring [Member] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	1
Liabilities [Abstract]
Derivative contracts - liabilities	18	18
Fair value, measurements, recurring [Member] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	2	1
Liabilities [Abstract]
Derivative contracts - liabilities	3	2
Fair value, measurements, recurring [Member] | Level 1 [Member]
Assets [Abstract]
Total return swaps	0	0
Total assets	0	0
Liabilities [Abstract]
Contingent consideration	0
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] | Level 1 [Member] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] | Level 1 [Member] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] | Level 2 [Member]
Assets [Abstract]
Total return swaps	2	4
Total assets	4	6
Liabilities [Abstract]
Contingent consideration	0
Total liabilities	21	20
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] | Level 2 [Member] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	1
Liabilities [Abstract]
Derivative contracts - liabilities	18	18
Fair value, measurements, recurring [Member] | Level 2 [Member] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	2	1
Liabilities [Abstract]
Derivative contracts - liabilities	3	2
Fair value, measurements, recurring [Member] | Level 3 [Member]
Assets [Abstract]
Total return swaps	0	0
Total assets	0	0
Liabilities [Abstract]
Contingent consideration	49
Total liabilities	49	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	832	864
Fair value, measurements, recurring [Member] | Level 3 [Member] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] | Level 3 [Member] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	$ 0	$ 0

Debt - Revolving Credit Agreeme

Debt - Revolving Credit Agreement Narrative (Details) - Revolving Credit Agreement [Member] - USD ($) $ in Millions		9 Months Ended	12 Months Ended
	Aug. 20, 2021	Sep. 28, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Line of credit initiation date	Aug. 20, 2021	Jul. 11, 2023
Credit facility borrowing capacity		$ 1,000
Credit facility expiration date		Jul. 11, 2028
Line of credit interest rate		4.96%	5.36%
Debt instrument, basis spread on variable rate		1.18%	1%
Line of credit combined interest rate		6.14%	6.36%
Borrowings		$ 50	$ 200
Outstanding letters of credit provided to third parties		11	$ 10
Average amount outstanding		$ 64

Debt - Other Short-Term Bank Cr

Debt - Other Short-Term Bank Credit Lines Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Bank credit lines	$ 638	$ 264
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity	689	368
Bank credit lines	$ 588	$ 64
Weighted average interest rate on borrowings under credit lines at period end	5.94%	6.02%
Average amount outstanding	$ 426

Debt - Private Placement Facili

Debt - Private Placement Facilities Narrative (Details) - Private Placement Facilities [Member]	9 Months Ended
	Sep. 28, 2024 USD ($)
Debt Instrument [Line Items]
Number of companies included in private placement facilities	4
Debt instrument maximum borrowing capacity	$ 1,500,000,000
Debt instrument, maturity date	Oct. 20, 2026
Average term of issuances under private placement facilities	12 years
Weighted average interest rate at period end	3.66%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years

Debt - Term Loan Narrative (Det

Debt - Term Loan Narrative (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 28, 2024	Dec. 30, 2023
Term Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt face amount	$ 750
Debt term (in years)	3 years
Long-term debt	$ 722	$ 741
Debt instrument, interest rate, stated percentage	5.10%	5.36%
Debt instrument, basis spread on variable rate	1.60%	1.35%
Debt instrument, interest rate at period end	6.70%	6.71%
Debt Instrument Variable Interest Rate Type Extensible Enumeration	Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]	Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]
Debt instrument, maturity date	Jul. 11, 2026
Term Credit Agreement [Member] | Interest Rate Swap [Member]
Line of Credit Facility [Line Items]
Derivative fixed interest rate	6.04%	5.79%
September 2024 through June 2026 [Member]
Line of Credit Facility [Line Items]
Quarterly payments	$ 9
September 2023 through June 2024 [Member]
Line of Credit Facility [Line Items]
Quarterly payments	$ 5

Debt - U.S. Trade Accounts Rece

Debt - U.S. Trade Accounts Receivable Securitization Narrative (Details) - U.S. Trade Accounts Receivable Securitization [Member] $ in Millions	9 Months Ended	12 Months Ended
	Sep. 28, 2024 USD ($) number	Dec. 30, 2023 USD ($)
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt instrument, maturity date	Dec. 15, 2025
Debt instrument maximum borrowing capacity	$ 450
Long-term debt	$ 210	$ 210
Debt instrument, interest rate at period end	5.28%	5.67%
Debt instrument, basis spread on variable rate	0.75%	0.75%
Debt instrument, variable rate basis at period end	6.03%	6.42%
Debt Instrument Variable Interest Rate Type Extensible Enumeration	Average Asset Backed Commercial Paper Rate [Member]	Average Asset Backed Commercial Paper Rate [Member]
Number of banks as agents for debt instrument | number	2
Minimum [Member]
Debt Instrument [Line Items]
Commitment fee basis points depending upon program utilization	0.0030
Maximum [Member]
Debt Instrument [Line Items]
Commitment fee basis points depending upon program utilization	0.0035

Debt - Schedule of Bank Credit

Debt - Schedule of Bank Credit Lines (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Bank Credit lines	$ 638	$ 264
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	50	200
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 588	$ 64

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Millions		Sep. 28, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Finance lease obligations		$ 7	$ 8
Total		2,015	2,087
Less current maturities		(109)	(150)
Long-term debt	[1]	1,906	1,937
Term Credit Agreement [Member]
Debt Instrument [Line Items]
Long-term debt		$ 722	$ 741
Borrowing Rate		5.10%	5.36%
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Long-term debt		$ 1,024	$ 1,074
U.S. Trade Accounts Receivable Securitization [Member]
Debt Instrument [Line Items]
Long-term debt		210	210
Various collateralized and uncollateralized loans payable with interest, in varying installments through 2031 at interest rates from 0.00% to 9.42% at September 28, 2024 and from 0.00% to 9.42% at December 30, 2023 [Member]
Debt Instrument [Line Items]
Long-term debt		$ 52	$ 54
Various collateralized and uncollateralized loans payable with interest, in varying installments through 2031 at interest rates from 0.00% to 9.42% at September 28, 2024 and from 0.00% to 9.42% at December 30, 2023 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Borrowing Rate		0%	0%
Various collateralized and uncollateralized loans payable with interest, in varying installments through 2031 at interest rates from 0.00% to 9.42% at September 28, 2024 and from 0.00% to 9.42% at December 30, 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Borrowing Rate		9.42%	9.42%
[1] Amounts presented include balances held by our consolidated variable interest entity (“VIE”). December 30, 2023, includes trade accounts receivable of $ 341 284 210 million and $ 210

Debt - Schedule of Private Plac

Debt - Schedule of Private Placement Facility Borrowings (Details) - Private Placement Facilities [Member] - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1)
Total	$ 1,024	$ 1,074
Debt Instrument, Maturity Date	Oct. 20, 2026
Private Placement Facilities 1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Dec. 24, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3%
Debt Instrument, Maturity Date	Dec. 24, 2024
Private Placement Facilities 2 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 16, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.42%
Debt Instrument, Maturity Date	Jun. 16, 2027
Private Placement Facilities 3 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 15, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.52%
Debt Instrument, Maturity Date	Sep. 15, 2029
Private Placement Facilities 4 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 02, 2018
Long-term Debt, Gross	$ 100
Borrowing Rate	3.32%
Debt Instrument, Maturity Date	Jan. 02, 2028
Private Placement facilities 5 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 02, 2020
Long-term Debt, Gross	$ 100
Borrowing Rate	2.35%
Debt Instrument, Maturity Date	Sep. 02, 2030
Private Placement Facilities 6 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.48%
Debt Instrument, Maturity Date	Jun. 02, 2031
Private Placement Facilities 7 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.58%
Debt Instrument, Maturity Date	Jun. 02, 2033
Private Placement Facilities 8 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.79%
Debt Instrument, Maturity Date	May 04, 2028
Private Placement Facilities 9 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.84%
Debt Instrument, Maturity Date	May 04, 2030
Private Placement Facilities 10 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.96%
Debt Instrument, Maturity Date	May 04, 2033
Private Placement Facilities 11 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 150
Borrowing Rate	4.94%
Debt Instrument, Maturity Date	May 04, 2033

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Income Tax Examination [Line Items]
Effective tax rate	25.10%	22.50%
Tax interest expense (credit)	$ 1	$ 3
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	107		$ 115
Unrecognized tax benefits that would affect the effective tax rate if recognized	99		107
Total interest	$ 18		$ 16

Plans of Restructuring - Narrat

Plans of Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 48	$ 11	$ 73	$ 59
2022 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	12	$ 11	37	$ 59
2024 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 36		$ 36

Plans of Restructuring - Schedu

Plans of Restructuring - Schedule of Restructuring Costs and Integration Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 48	$ 11	$ 73	$ 59
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	38		61
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	10		12
2024 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	36		36
2024 Plan [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	31		31
2024 Plan [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	4		4
2024 Plan [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1		1
2024 Plan [Member] | Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	29		29
2024 Plan [Member] | Health Care Distribution [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	26		26
2024 Plan [Member] | Health Care Distribution [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2		2
2024 Plan [Member] | Health Care Distribution [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1		1
2024 Plan [Member] | Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	7		7
2024 Plan [Member] | Technology and Value-Added Services [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	5		5
2024 Plan [Member] | Technology and Value-Added Services [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2		2
2024 Plan [Member] | Technology and Value-Added Services [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0
2022 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	12	11	37	59
2022 Plan [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	8	6	24	40
2022 Plan [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	4	7	14
2022 Plan [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3	1	6	4
2022 Plan [Member] | Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		0		1
2022 Plan [Member] | Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	9	10	32	52
2022 Plan [Member] | Health Care Distribution [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	7	6	21	36
2022 Plan [Member] | Health Care Distribution [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	3	7	12
2022 Plan [Member] | Health Care Distribution [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	1	4	3
2022 Plan [Member] | Health Care Distribution [Member] | Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		0		1
2022 Plan [Member] | Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3	1	5	7
2022 Plan [Member] | Technology and Value-Added Services [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	0	3	4
2022 Plan [Member] | Technology and Value-Added Services [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0	1	0	2
2022 Plan [Member] | Technology and Value-Added Services [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 2	0	$ 2	1
2022 Plan [Member] | Technology and Value-Added Services [Member] | Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		$ 0		$ 0

Plans of Restructuring - Sche_2

Plans of Restructuring - Schedule of Restructuring Reserve by Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Balance, beginning			$ 23
Restructuring costs	$ 48	$ 11	73	$ 59
Non-cash accelerated depreciation and amortization			(11)	(13)
Cash payments and other adjustments			(42)
Balance, ending	43		43
2022 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			23
Restructuring costs	12	$ 11	37	$ 59
Non-cash accelerated depreciation and amortization			(7)
Cash payments and other adjustments			(35)
Balance, ending	18		18
2024 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			0
Restructuring costs	36		36
Non-cash accelerated depreciation and amortization			(4)
Cash payments and other adjustments			(7)
Balance, ending	$ 25		$ 25

Legal Proceedings - Narrative (

Legal Proceedings - Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 28, 2024 USD ($) claims	Sep. 30, 2023 USD ($)	Sep. 28, 2024 USD ($) claims	Sep. 30, 2023 USD ($)	Dec. 30, 2023 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 3,174	$ 3,162	$ 9,482	$ 9,322
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number | claims	175		175
Actions Consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage					0.40%
Actions Consolidated in the MultiDistrict Litigation [Member] | Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues					$ 12,300
Other Hospitals Located throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs			25
Cruz-Bermudez Action [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Litigation Settlement, Amount Awarded to Other Party	$ 2.9

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)			2 years 7 months 6 days
Grants in period (in shares)			0
Total unrecognized compensation cost related to non-vested awards	$ 83		$ 83
Pre-tax share-based compensation (Credit) expense	$ 10	$ 14	$ 30	$ 38
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years
Percentage of stock options vest per year			33.33%
Expiration period (in years)			10 years
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			4 years
Time-Based Restricted Stock/Restricted Units [Member] | 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			12 months
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity under the Plans (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 28, 2024
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	1,078,459
Exercised (in shares)	(48,842)
Forfeited (in shares)	(10,980)
Outstanding at end of period (in shares)	1,018,637
Weighted Average Exercise Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 71.46
Exercised (in dollars per share)	62.71
Forfeited (in dollars per share)	85.31
Outstanding at end of period (in dollars per share)	$ 71.73
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	6 years 9 months 18 days
Outstanding at end of period, Aggregate Intrinsic Value	$ 6
Options exercisable (in shares)	887,589
Weighted average exercise price, options exercisable (in dollars per share)	$ 69.70

Stock-Based Compensation - Intr

Stock-Based Compensation - Intrinsic Values (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 28, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options | shares	131,048
Weighted Average Exercise Price | $ / shares	$ 85.51
Weighted Average Remaining Contractual Life (in years)	7 years 6 months
Aggregate Intrinsic Value | $	$ 0

Stock-Based Compensation - Stat

Stock-Based Compensation - Status of Unvested RSUs (Details)	9 Months Ended
	Sep. 28, 2024 $ / shares shares
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) | shares	1,655,393
Granted (in shares) | shares	465,339
Vested (in shares) | shares	(329,115)
Forfeited (in shares) | shares	(87,304)
Ending balance outstanding (in shares) | shares	1,704,313
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 70.34
Granted (in dollars per share)	75.83
Vested (in dollars per share)	63
Forfeited (in dollars per share)	77.19
Ending balance outstanding (in dollars per share)	72.92
Aggregate intrinsic value	$ 73.22
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) | shares	208,742
Granted (in shares) | shares	329,118
Vested (in shares) | shares	(8,262)
Forfeited (in shares) | shares	(55,976)
Ending balance outstanding (in shares) | shares	473,622
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 78.02
Granted (in dollars per share)	76.70
Vested (in dollars per share)	66.53
Forfeited (in dollars per share)	79.69
Ending balance outstanding (in dollars per share)	75.91
Aggregate intrinsic value	$ 73.22

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interests - Components of the Change in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period			$ 864	$ 576	$ 576
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries			(257)		(19)
Increase in redeemable noncontrolling interests due to business acquisitions			172		326
Net income (loss) attributable to redeemable noncontrolling interests	$ (1)	$ 2	0	11	6
Distributions declared, net of capital contributions			(30)		(19)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	11	$ (2)	(4)	$ (1)	5
Change in fair value of redeemable securities			87		(11)
Balance, end of period	$ 832		$ 832		$ 864

Comprehensive Income - Accumula

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (36)		$ (36)		$ (32)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	0		0		(1)
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(243)		(243)		(188)
Unrealized gain (loss) from hedging activities	(16)		(16)		(13)
Pension adjustment loss	(5)		(5)		(5)
Accumulated other comprehensive loss	(264)		(264)		(206)
Total Accumulated other comprehensive loss	(300)		(300)		$ (239)
Components of Comprehensive Income
Net Income (loss)	99	$ 143	302	$ 419
Foreign currency translation gain (loss)	58	(45)	(58)	(17)
Tax effect	0	0	0	0
Foreign currency translation gain (loss)	58	(45)	(58)	(17)
Unrealized gain (loss) from hedging activities	(25)	9	(4)	3
Tax effect	7	(3)	1	(1)
Unrealized gain (loss) from hedging activities	(18)	6	(3)	2
Comprehensive income	$ 139	$ 104	$ 241	$ 404

Comprehensive Income - Total Co

Comprehensive Income - Total Comprehensive Income, Net of Applicable Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 127	$ 100	$ 238	$ 384
Comprehensive income attributable to noncontrolling interests	0	4	7	10
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	12	0	(4)	10
Comprehensive income	$ 139	$ 104	$ 241	$ 404

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Weighted-average common shares outstanding:
Basic (in shares)	126,124,715	130,388,353	127,550,045	130,888,717
Effect of dilutive securities:
Stock options and restricted stock units	930,219	1,053,782	948,449	1,260,455
Diluted (in shares)	127,054,934	131,442,135	128,498,494	132,149,172

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	430,201	431,367	432,404	441,309
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	412,574	424,005	416,065	426,237
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	17,627	7,362	16,339	15,072

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Supplemental Cash Flow Information [Abstract]
Interest			$ 92	$ 52
Income taxes			127	178
Non-cash net unrealized gains related to foreign currency hedging activities	$ (25)	$ 9	$ (4)	$ 3

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Related Party Transaction [Line Items]
Current operating lease liabilities	$ 77		$ 77		$ 80
Noncurrent operating lease liabilities	262		262		310
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Other liabilities	8		8		5
Due from related party	32		32		32
Revenues	14	$ 11	38	$ 34
Purchases from related party	2	1	8	7
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Other liabilities	10		$ 10		1
Internet Brands Inc [Member] | Royalty Agreements [Member]
Related Party Transaction [Line Items]
Period covered by agreement			10 years
Related party agreement amount			$ 31
Operating costs and expenses	8	$ 8	23	$ 23
Employees and Minority Shareholders [Member]
Related Party Transaction [Line Items]
Current operating lease liabilities	6		6		5
Noncurrent operating lease liabilities	$ 22		$ 22		$ 23
Employees and Minority Shareholders [Member] | Operating Lease Liabilities, Current [Member] | Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			7.40%		6.30%
Employees and Minority Shareholders [Member] | Operating Lease Liabilities, Non-Current [Member] | Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			8.30%		7.40%
Employees and Minority Shareholders [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	6 months		6 months
Employees and Minority Shareholders [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	13 years		13 years